ContractCommercial Manufacturing and Supply Agreement • May 14th, 2021 • Roivant Sciences Ltd. • Delaware
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE DERMAVANT SCIENCES LTD. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO DERMAVANT SCIENCES LTD. IF PUBLICLY DISCLOSED.
COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENTCommercial Manufacturing and Supply Agreement • March 8th, 2018 • Dynavax Technologies Corp • Pharmaceutical preparations • Delaware
This Commercial Manufacturing and Supply Agreement (this “Agreement”) is made effective as of the 22nd day of November, 2013 (the “Effective Date”) by and between Baxter Pharmaceutical Solutions LLC, a Delaware limited liability company having a place of business at 927 South Curry Pike, Bloomington, Indiana 47403 (“Baxter”), and Dynavax Technologies Corporation, a Delaware corporation having a principal place of business at 2929 Seventh Street, Suite 100, Berkeley. California 94710 (“Dynavax”).
ContractCommercial Manufacturing and Supply Agreement • March 15th, 2013 • Zogenix, Inc. • Pharmaceutical preparations • New York
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
INDICATES CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENTCommercial Manufacturing and Supply Agreement • June 12th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
This Commercial MANUFACTURING Supply Agreement (this “Agreement”) is made effective as of the ______ day of _____, 2011 (“Effective Date”) by and between Baxter Oncology GmbH, with an address at Kantstrasse 2, 33790 Halle / Westphalia, Germany, as such term is defined herein (“Baxter”) and OASMIA PHARMACEUTICAL AB, a Swedish corporation, having offices at Vallongatan 1, SE 752 28 Uppsala Sweden (“Client” or “Oasmia”).
ContractCommercial Manufacturing and Supply Agreement • September 3rd, 2010 • Zogenix, Inc. • Pharmaceutical preparations
CERTAIN MATERIAL (INDICATED BY AND ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMISSION.
FIRST AMENDMENT TO COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENTCommercial Manufacturing and Supply Agreement • November 4th, 2021 • Dynavax Technologies Corp • Pharmaceutical preparations
THIS FIRST AMENDMENT TO COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENT (“First Amendment”) is entered into as of the 10th day of September, 2021 (“First Amendment Effective Date”), by and between BAXTER PHARMACEUTICAL SOLUTIONS LLC, a Delaware limited liability company having a place of business at 927 South Curry Pike, Bloomington, Indiana 47403 (“Baxter”), and DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation having a principal place of business at 2100 Powell Street, Suite 900, Emeryville, California 94608 (“Dynavax”).
FIRST AMENDMENT TO COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENTCommercial Manufacturing and Supply Agreement • November 6th, 2014 • Zogenix, Inc. • Pharmaceutical preparations • New York
This First Amendment to the Commercial Supply Agreement (as defined below) (the "First Amendment") is made and entered into as of 12th day of September 2014 (“First Amendment Effective Date”).
COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENTCommercial Manufacturing and Supply Agreement • May 10th, 2023 • IVERIC Bio, Inc. • Pharmaceutical preparations • New York
This Commercial Manufacturing and Supply Agreement (this “Agreement”) is entered into by and between AGILENT TECHNOLOGIES, INC., a Delaware corporation, having a principal office at 5301 Stevens Creek Blvd., Santa Clara, CA 95051 (“Agilent”) and IVERIC BIO, INC., a Delaware corporation, having a principal office at 8 Sylvan Way, Parsippany, NJ 07054 (“Customer”) effective as of March 14, 2023 (the “Effective Date”). Agilent and Customer are each referred to herein as a “Party” and together as the “Parties”.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENTCommercial Manufacturing and Supply Agreement • November 5th, 2015 • Ophthotech Corp. • Pharmaceutical preparations • New York
This Commercial Manufacturing and Supply Agreement (this “Agreement”) is entered into by and between AGILENT TECHNOLOGIES, INC., a Delaware corporation, having a principal office at 5301 Stevens Creek Blvd., Santa Clara, CA 95051 (“Agilent”) and OPHTHOTECH CORPORATION, a Delaware corporation, having a principal office at One Penn Plaza, Suite 1924, New York, NY 10119 (“Customer”) effective as of September 3, 2015 (the “Effective Date”). Agilent and Customer are each referred to herein as a “Party” and together as the “Parties”.
COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENTCommercial Manufacturing and Supply Agreement • August 14th, 2015 • Oasmia Pharmaceutical AB • Pharmaceutical preparations
This Commercial MANUFACTURING Supply Agreement (this “Agreement”) is made effective as of the 16th day of February, 2011 (“Effective Date”) by and between Baxter Oncology GmbH, with an address at Kantstrasse 2, 33790 Halle / Westphalia, Germany, as such term is defined herein (“Baxter”) and OASMIA PHARMACEUTICAL AB, a Swedish corporation, having offices at Vallongatan 1, SE 752 28 Uppsala Sweden (“Client” or “Oasmia”).
